Clinical Validity of Imatinib Therapeutic Drug Monitoring in a Real-World Italian Cohort of Gastrointestinal Stromal Tumors and the Role of Patients' Sex.
文献摘要
Background : Substantial inter-individual variability in imatinib systemic exposure may influence both efficacy and toxicity. Based on recommendations of the International Association for Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), the IRCCS-CRO of Aviano started in 2018 offering physicians the opportunity to monitor plasma concentrations of imatinib and its active metabolite, norimatinib, as part of a diagnostic service for patients with Gastrointestinal Stromal Tumor (GIST). This study aims to evaluate the potential clinical utility of imatinib Therapeutic Drug Monitoring (TDM) in predicting response and toxicity in a real-world cohort of 63 patients with GIST. Methods : Imatinib and its active metabolite norimatinib trough concentrations (C min ) were quantified using a validated LC-MS/MS method. Associations between drug exposure and clinical-demographic characteristics, treatment-related toxicity, and progression-free survival (PFS) were evaluated. Results : A total of 437 plasma samples from 63 patients were collected. Marked inter- and intra-patient variability in imatinib exposure was observed (43% and 31% respectively); 67% of patients receiving 400 mg/day had a C min below the recommended target concentration (1100 ng/mL). Female sex was significantly associated with higher imatinib exposure (median C min 1114 vs. 786 ng/mL in males; p = 0.0018). Combined age-sex analysis showed a significant difference between women and men p = 0.0068, Bonferroni-adjusted). A strong exposure-toxicity relationship emerged, with higher imatinib levels in samples collected at toxicity occurrence vs. the others (1728 vs. 927 ng/mL; p min and PFS was observed; however, disease progression was more frequent in patients with C min min >1500 ng/mL (60% vs. 0%, respectively). Conclusions : TDM was found to be a potentially useful tool for predicting clinically relevant toxicity and outcome. Sex and age significantly influence exposure, supporting tailored dosing strategies.